Back to Search Start Over

Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients

Authors :
Kevin T. Savage
Martina L. Porter
Kelsey S. Flood
Monica Rosales Santillan
Alexa B. Kimball
Alexandra Charrow
Source :
JAAD Case Reports, Vol 6, Iss 2, Pp 99-102 (2020), JAAD Case Reports
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by inflammatory nodules, abscesses, and fistulae. Severe disease is frequently treated with adalimumab or infliximab, but limited research and insurance coverage confine treatment options. Often, aggressive multifaceted therapeutic regimens fail in severe cases. The Janus kinase (JAK) inhibitor, tofacitinib, acts through the JAK-STAT pathway, suppressing inflammatory cytokines implicated in HS pathogenesis, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α.1 JAK inhibitors may benefit HS patients who lack response to targeted biologic therapy. We report on 2 patients with a rare, recalcitrant, ulcerating HS phenotype who, despite not responding to numerous treatments, including biologics (Table I), exhibited prolonged response to a tofacitinib multimodal regimen. Table I Baseline patient characteristics

Details

ISSN :
23525126
Volume :
6
Database :
OpenAIRE
Journal :
JAAD Case Reports
Accession number :
edsair.doi.dedup.....2bf67b0a069580bc5075f452e6667e12
Full Text :
https://doi.org/10.1016/j.jdcr.2019.10.010